Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well depsipeptide (romidepsin) works in treating patients
with recurrent ovarian epithelial or peritoneal cavity cancer. Drugs used in chemotherapy,
such as depsipeptide (romidepsin), work in different ways to stop tumor cells from dividing
so they stop growing or die. Depsipeptide (romidepsin) may also stop the growth of ovarian
epithelial or peritoneal cavity cancer by stopping blood flow to the tumor and by blocking
the enzymes necessary for their growth